Patent intelligence · US
US 11254940
Inhibition of MAP4K4 through RNAi
Inhibition of MAP4K4 through RNAi
Patent details — US 11254940
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 22, 2022
- Expiration
- Feb 17, 2042
- Applicant
- Phio Pharmaceuticals Corp.
- Claims
- 9
- CPC classes
- A61P, A61P17/06, A61P27/02, A61P29/00
Quick answer
US 11254940 (Inhibition of MAP4K4 through RNAi) is held by Phio Pharmaceuticals Corp.. Status: granted. Granted Feb 22, 2022. Expires Feb 17, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Phio Pharmaceuticals Corp.
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61P, A61P17/06, A61P27/02, A61P29/00, A61P3/00, A61P3/04
More from Phio Pharmaceuticals Corp.
Related pharmaceutical patents in our USPTO index.
-
US 11926828
Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1
granted -
US 11639359
Bryoid compositions, methods of making and use thereof
granted -
US 11584933
RNA interference in ocular indications
granted -
US 11396654
Neutral nanotransporters
granted -
US 11279934
Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
granted -
US 11234932
Combination HIV therapeutic
granted -
US 11118178
Reduced size self-delivering RNAI compounds
granted
Frequently asked questions
What is US patent 11254940?
US 11254940 (Inhibition of MAP4K4 through RNAi) is held by Phio Pharmaceuticals Corp.. Status: granted. Granted Feb 22, 2022. Expires Feb 17, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11254940?
Phio Pharmaceuticals Corp. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 39 pharmaceutical patents for this assignee.
When does US 11254940 expire?
Our index shows an expiration date of Feb 17, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.